Methods for treating ocular inflammatory diseases
First Claim
1. A method of treating blepharitis having as its pathophysiological origin bacteria, the method comprising administering twice daily to the affected eye of a subject who has said blepharitis, for 14 days or more, a composition comprising an active ingredient consisting of about 0.1% by weight dexamethasone in an ophthalmically acceptable vehicle,wherein the ophthalmically acceptable vehicle comprises an aqueous polymer suspension comprising a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and an initial viscosity in a range from about 1,000 to about 30,000 centipoises, and which gels on contact with tear fluid,wherein the method does not comprise administration of an antibiotic.
10 Assignments
0 Petitions
Accused Products
Abstract
A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.
-
Citations
3 Claims
-
1. A method of treating blepharitis having as its pathophysiological origin bacteria, the method comprising administering twice daily to the affected eye of a subject who has said blepharitis, for 14 days or more, a composition comprising an active ingredient consisting of about 0.1% by weight dexamethasone in an ophthalmically acceptable vehicle,
wherein the ophthalmically acceptable vehicle comprises an aqueous polymer suspension comprising a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and an initial viscosity in a range from about 1,000 to about 30,000 centipoises, and which gels on contact with tear fluid, wherein the method does not comprise administration of an antibiotic.
Specification